All Novo Nordisk articles
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
ResearchInsulin medicines more resilient to temperature than previously thought
Review suggests more lenient storage guidelines could make diabetes treatments more accessible
-
BusinessThe diabetes drugs aiming to aid weight loss
Can peptide hormone mimics avoid the side effect pitfalls of previous weight loss treatments?
-
BusinessUniversity–industry collaborations aspire to pharmaceutical innovation
Three new UK partnerships illustrate drug research co-operation approaches that are growing in popularity
-
BusinessNovo Nordisk to axe 1000 jobs
Diabetes specialist is cutting costs in the face of increased competition
-
-
Business
Novo Nordisk quits inflammation R&D and cuts jobs
Firm will return to primary focus on diabetes and obesity
-
Business
Novo Nordisk to create 6000 jobs by 2022
Half of the new Danish employees will be in R&D roles